These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 23883294)

  • 1. Preferred treatment frequency in patients receiving androgen deprivation therapy for advanced prostate cancer.
    Fode M; Nielsen TK; Al-Hamadani M; Andersen JR; Jakobsen H; Sønksen J
    Scand J Urol; 2014 Apr; 48(2):183-8. PubMed ID: 23883294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient preference on once-daily oral versus injectable androgen deprivation therapy for Asian patients with advanced prostate cancer.
    Wong HC; Cheung BC; Yuen VW; Teoh JY; Chiu PK; Ng CF
    Int Urol Nephrol; 2024 Sep; 56(9):2923-2928. PubMed ID: 38512441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Information needs of men on androgen deprivation therapy.
    Soeyonggo T; Warde P; Fleshner N; Timilshina N; Alibhai SM
    BJU Int; 2012 May; 109(10):1503-9. PubMed ID: 21883845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
    Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis.
    Hauber B; Hong A; Hunsche E; Maculaitis MC; Collins SP
    Adv Ther; 2024 Oct; 41(10):3934-3950. PubMed ID: 39167332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Traditional androgen ablation approaches to advanced prostate cancer: new insights.
    Rove KO; Crawford ED
    Can J Urol; 2014 Apr; 21(2 Supp 1):14-21. PubMed ID: 24775719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
    Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
    Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostate cancer treated with androgen deprivation therapy: Care and monitoring in daily practice].
    Hennequin C; Bruyère F; Sedefdjian A; Bourouina R; Rouprêt M
    Prog Urol; 2015 Dec; 25(16):1132-9. PubMed ID: 26455778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE.
    Aaronson D; Cowan J; Carroll P; Konety B
    BJU Int; 2010 Apr; 105(7):951-5. PubMed ID: 19889066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
    Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
    Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
    BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
    Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
    Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.
    Malik R; Jani AB; Liauw SL
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1022-8. PubMed ID: 20510547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.